Upcoming diagnostic biomarkers with promising prospects in neurological disorders.
An exponential grade prevalence in neurological disorders strains substantial steps to be taken for their prevention and treatment. The neurodiagnostic biomarkers are gaining momentum presently in order to enhance the diagnostic accuracy of neurodegenerative disorder, to assess its advancement precisely and to monitor therapeutic efficiency of therapeutic interventions. Therefore, the primary focus of the present review is the recent development in this field of neurodiagnostic biomarkers, and the current stature of biomarker exploration in the context of various neurodegenerative disease. This review encompasses an updated and detail account of specific (β-Amyloid, Tau and Phospho-tau 181, Tar-DNA binding protein-43, Progranulin, a-synuclein, Clusterin, etc.) and non-specific (genetic, synaptic, inflammatory and coagulation) neurodiagnostic biomarkers and the recent advances in this growing field. This comprehensive review also suggests the utilization of neurodiagnostic markers in network approaches and personalized medication that will eventually improvise the existing diagnostic and therapeutic complexities of neurodiagnostic biomarkers.